肿瘤浸润 PD-1CD8 T 细胞上的 Tim-3 表达与肾细胞癌的临床预后不良相关。
Tim-3 Expression on Tumor-Infiltrating PD-1CD8 T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma.
机构信息
INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France.
Department of Urology, Hôpital Européen Georges Pompidou, Paris, France.
出版信息
Cancer Res. 2017 Mar 1;77(5):1075-1082. doi: 10.1158/0008-5472.CAN-16-0274. Epub 2016 Nov 21.
Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8 T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8 T cells coexpressing PD-1 and Tim-3 correlated with an aggressive phenotype and a larger tumor size at diagnosis. Coexpression of PD-1 and Tim-3 above the median conferred a higher risk of relapse and a poorer 36-month overall survival. Notably, other CD8T-cell subsets did not exert a similar effect on overall survival. Moreover, only the PD-1Tim-3 subset of CD8 T cells exhibited impaired function after stimulation. Our findings establish intratumoral Tim-3PD1CD8 T cells as critical mediators of an aggressive phenotype in RCC. Use of the Vectra tool may be useful to identify similarly critical prognostic and predictive biomarkers in other tumor types and their response to immunotherapy. .
T 细胞表达的抑制性受体介导对肿瘤抗原的耐受,这些受体的共表达加剧了这种功能失调状态。我们使用 VectraR 自动化多参数免疫荧光技术,从肾细胞癌(RCC)患者中定量分析了共表达抑制性受体 PD-1 和 Tim-3 的肿瘤内 CD8 T 细胞。第二个验证队列通过细胞术测量了相同的参数。肿瘤浸润性 CD8 T 细胞共表达 PD-1 和 Tim-3 的百分比与侵袭性表型和诊断时更大的肿瘤大小相关。中位以上的 PD-1 和 Tim-3 共表达预示着更高的复发风险和 36 个月总体生存率较差。值得注意的是,其他 CD8T 细胞亚群对总体生存率没有类似的影响。此外,只有 CD8 T 细胞的 PD-1Tim-3 亚群在刺激后表现出功能受损。我们的研究结果确立了肿瘤内 Tim-3PD1CD8 T 细胞作为 RCC 侵袭性表型的关键介质。Vectra 工具的使用可能有助于在其他肿瘤类型及其对免疫治疗的反应中识别类似的关键预后和预测生物标志物。